Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-28
DOI
10.3389/fimmu.2021.692157
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
- (2020) Maria T. Georgescu et al. Frontiers in Immunology
- Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity
- (2019) H. A. Daniel Lagassé et al. AAPS Journal
- Functional diversification of IgGs through Fc glycosylation
- (2019) Taia T. Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis
- (2018) M. Carcao et al. HAEMOPHILIA
- Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases
- (2018) Akhilesh Kumar Shakya et al. TRENDS IN BIOTECHNOLOGY
- Factor VIII inhibitors: Advances in basic and translational science
- (2017) J. D. Lai et al. International Journal of Laboratory Hematology
- IgG Fc engineering to modulate antibody effector functions
- (2017) Xinhua Wang et al. Protein & Cell
- Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
- (2017) Aura Muntasell et al. Frontiers in Immunology
- Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
- (2016) S. W. Pipe et al. BLOOD
- Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
- (2016) Sriram Krishnamoorthy et al. CELLULAR IMMUNOLOGY
- Extended half-life factor VIII for immune tolerance induction in haemophilia
- (2016) L. M. Malec et al. HAEMOPHILIA
- Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein
- (2016) Charles L. Groomes et al. PEDIATRIC BLOOD & CANCER
- What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?
- (2016) M. Janbain et al. Hematology-American Society of Hematology Education Program
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
- (2015) William R. Strohl BIODRUGS
- Mouse and human FcR effector functions
- (2015) Pierre Bruhns et al. IMMUNOLOGICAL REVIEWS
- Fc fusion as a platform technology: potential for modulating immunogenicity
- (2015) Ditza Levin et al. TRENDS IN BIOTECHNOLOGY
- FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
- (2015) Falk Nimmerjahn et al. TRENDS IN IMMUNOLOGY
- Inhibitor eradication with rituximab in haemophilia: where do we stand?
- (2014) Massimo Franchini et al. BRITISH JOURNAL OF HAEMATOLOGY
- Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies
- (2014) Zhijie Jey Cheng et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Type I and type II Fc receptors regulate innate and adaptive immunity
- (2014) Andrew Pincetic et al. NATURE IMMUNOLOGY
- Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
- (2013) Timo Rath et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- A Comprehensive Mathematical Model for Three-Body Binding Equilibria
- (2013) Eugene F. Douglass et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
- (2012) J. A. Dumont et al. BLOOD
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
- (2012) J. S. Powell et al. BLOOD
- F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
- (2012) S. C. Gouw et al. BLOOD
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- Introduction to current and future protein therapeutics: A protein engineering perspective
- (2011) Paul J. Carter EXPERIMENTAL CELL RESEARCH
- Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies
- (2011) Alain Beck et al. mAbs
- Design of Targeted B Cell Killing Agents
- (2011) Alexey V. Stepanov et al. PLoS One
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches
- (2010) Antonio Coppola et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance
- (2009) V. TERRAUBE et al. HAEMOPHILIA
- The molecular mechanisms of immunomodulation and tolerance induction to factor VIII
- (2009) B. WATERS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started